Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.
Vincent Lo ReDena M CarbonariM Elle SaineCraig W NewcombJason A RoyQing LiuQufei WuSerena CardilloKevin HaynesStephen E KimmelPeter P ReeseDavid J MargolisAndrea J ApterK Rajender ReddySean HennessyHarshvinder BhullarArlene M GallagherDaina B EspositoBrian L StromPublished in: BMJ open diabetes research & care (2017)
NCT01086280, NCT01086293, NCT01086319, NCT01086306, and NCT01377935; Results.